DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:

OBSERVATION 1

Investigations of an unexplained discrepancy and a failure of a batch or any of its components to meet any of its specifications did not extend to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy.

Specifically, your firm has documented 5 sterility failures since January 2016 to present.

<table>
<thead>
<tr>
<th>Date Compounded</th>
<th>Product</th>
<th>Lot Number</th>
<th>Sterility Failure Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/1/17</td>
<td>Thymosin Alpha</td>
<td>1101201705</td>
<td>11/15/17</td>
</tr>
<tr>
<td>10/30/17</td>
<td>IGF-1</td>
<td>10301704</td>
<td>11/15/17</td>
</tr>
<tr>
<td>12/20/17</td>
<td>IGF-1 LR3</td>
<td>12201709</td>
<td>1/10/18</td>
</tr>
<tr>
<td>1/24/18</td>
<td>BPC-157</td>
<td>01241805</td>
<td>2/13/18</td>
</tr>
<tr>
<td>1/24/18</td>
<td>HCG-4000</td>
<td>01241804</td>
<td>2/13/18</td>
</tr>
</tbody>
</table>

Your firm does not evaluate other products that were produced in the same time-period in which the sterility failure occurred. Per firm management, your firm performs a cleaning after a sterility failure, however, there is no written documentation that this additional cleaning of your ISO 5 and ISO 7 areas
OBSERVATION 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

a.) Your firm does not have any hold time studies for how long stoppers, vials and seals (caps) can be stored after being [b](4) prior to being used in sterile operations. On 8/21/18, we observed your pharmacy technician using the [b](4) stable operations while producing Thymosin Beta Injectable (lot# 0821201806), by [b](4) with their gloved hands.

b.) Media fills do not simulate your sterile operations process under normal operating conditions. Your media fills are not performed under worst case aseptic processing conditions, for example, your firm produces batches that consists of [b](4) vials during normal sterile operations under the ISO 5 hood, whereas your media fill consists of only [b](4) vials being filled and does not incorporate any interventions that may occur during sterile operations.

c.) Your firm does not include the [b](4) into the media fill program. No media fills are performed on the [b](4) process. For example, your firm produces the following two [b](4) products at your facility: Tesamorelin and HCG.

OBSERVATION 3
Protective apparel is not worn as necessary to protect drug products from contamination.
Specifically, on 8/21/18, while observing sterile operations, we observed a pharmacy technician enter the ISO 7 room, which your firm identifies as the USP 797 room. This room contains the ISO 5 hood. We observed your pharmacy technician enter your USP 797 room from your ISO 7 Ante room with ungloved hands (exposed skin). The Ante room is where the technician gowns and washes hands. Upon entering the USP 797 room, we observed the technician immediately apply (b) (4) to his ungloved hands. He then put on sterile gloves.

**OBSERVATION 4**

Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.

a.) Specifically, smoke studies are conducted every (b) (4) by a third-party. Your firm’s smoke studies were performed on (b) (4) . Prior to November 2017 your firm did not perform smoke studies. Your firm does not perform smoke studies under dynamic conditions. We reviewed your firm’s smoke studies and they were brief and had no description of what action was being performed. Furthermore, while viewing these smoke studies, it was difficult to see smoke on various occasions.

b.) Also, your firm does not include the (b) (4) process in your smoke studies. Your firm (b) (4) two products, Tesamorelin and HCG using a (b) (4) located inside the ISO 5 hood. The process includes (b) (4) vial, (b) (4) vials from the (b) (4) and (b) (4) vial (b) (4) from the (b) (4).

Your smoke studies are performed under static conditions and do not incorporate the (b) (4) process nor any dynamic conditions to evaluate the efficiency of your HEPA airflow.
OBSERVATION 5
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically, your firm’s bactericidal agent (b) (4) used for cleaning is not sterile. Your firm uses (b) (4) for cleaning the ISO 5 hood, ISO 7 rooms and ISO 8 rooms.

OBSERVATION 6
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

a.) Specifically, your firm only conducts personnel monitoring every (b) (4) on each individual that performs sterile operations. No other personnel monitoring is performed besides this (b) (4) monitoring. Your firm does not document the time when personnel monitoring is performed (i.e. before sterile operations, during sterile operations or after sterile operations). Your firm’s personnel monitoring consists of finger tips only. No other areas such as forehead, mask, or chest are monitored for the operators.

b.) Your firm does not have alarms connected to your magnehelic gauges to monitor pressure differentials during production. Furthermore, your firm only records the room pressures in the aseptic processing areas (b) (4) and does not monitor the magnehelic gauges during production.

OBSERVATION 7
Labeling materials issued for a batch were not carefully examined for identity and conformity to the labeling specified in the master or batch production records.

Specifically, on 9/11/18, we observed (b) 4 vials of Tesamorelin 1 mg subcutaneous injection (batch 07161804; BUD Date 07/12) stored in the refrigerator in your pharmacy. The Beyond Use Date (BUD) on each of the Tesamorelin vial labels of this lot contained an incorrect one-year BUD date, while the correct BUD date for Tesamorelin is 180 days.

Your firm began using a new computer program called (b) 4 on or about 7/6/18 for printing labels to be affixed to finished product vials. When this issue was brought to your management's attention, your firm conducted an investigation which identified that any Tesamorelin product produced and shipped between 7/6/18 to 9/11/18 contains the incorrect one year BUD date, due to an installation error of the new computer program.

**OBSERVATION 8**

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.

Specifically, your firm performs potency testing at various random intervals on products produced. However, there is no set schedule or frequency for when potency testing will be performed. Your firm's specification for potency is (b) 4% to (b) 4%. Your firm released 3 products to patients with Out-of-Specification (OOS) potency results.

<table>
<thead>
<tr>
<th>Product</th>
<th>Lot Number</th>
<th>BUD Date</th>
<th>Sterile/Non-Sterile</th>
<th>Date Produced</th>
<th>Test Date</th>
<th>Test Result</th>
<th>Released to patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glutathione 200mg</td>
<td>12191702</td>
<td>90</td>
<td>Sterile</td>
<td>12/19/17</td>
<td>1/10/18</td>
<td>92.5%</td>
<td>Yes - (b) 4</td>
</tr>
</tbody>
</table>
Furthermore, on potency results that are OOS your firm does not have a procedure in place on how to handle these failed results. Also, your firm did not conduct an investigation into each of these failed potency results that were released to patients.

**OBSERVATION 9**
Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.

a.) Specifically, your firm does not perform any identity testing on incoming raw materials.

b.) Your firm receives raw materials and peptides from suppliers both domestically and internationally. However, your firm has never audited any of these suppliers.

**OBSERVATION 10**
There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, there is no written stability program designed to assess the stability characteristics of drug products. For example, Glutathione 200mg Injection (lot 12191702) was not within its BUD date with a
88.0% potency result on 2/12/18 and Alprostadil/Papaverine/Phentolamine Injection 60mcg, 30 mg, 3 mg (lot 11141713) was not within its BUD date with a 83.2% potency result on 12/26/17.

<table>
<thead>
<tr>
<th>Product</th>
<th>Lot Number</th>
<th>BUD Date</th>
<th>Sterile/Non-Sterile</th>
<th>Date Produced</th>
<th>Test Date</th>
<th>Test Result</th>
<th>Released to patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glutathione 200mg Injection</td>
<td>12191702</td>
<td>90 Days</td>
<td>Sterile</td>
<td>12/19/17</td>
<td>1/10/18</td>
<td>92.5%</td>
<td>Yes - patient</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2/12/18</td>
<td>88.0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12/19/17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alprostadil/Papaverine/Phentolamine Injection</td>
<td>11141713</td>
<td>60 Days</td>
<td>Sterile</td>
<td>11/14/17</td>
<td>11/27/17</td>
<td>95.2%</td>
<td>Yes - patient</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12/26/17</td>
<td>83.2%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

OBSERVATION 11
Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.

Specifically, your firm does not have any hold time studies for how long glassware used for sterile operations can be stored before use after being depyrogenated in the (b) (4) Furthermore, your firm has not performed any studies to assure a 3-log reduction is achieved for endotoxins.

OBSERVATION 12
Routine calibration of equipment is not performed according to a written program designed to assure proper performance.
a.) Specifically, your firm uses **(b)(4)** for sterile operations of all high-risk sterile products (non-sterile to sterile products). The **(b)(4)** Temp pressure gauge (Serial Number: **(b)(4)**) used for performing the **(b)(4)** post sterile operations) has never been calibrated. This pressure gauge has been used since your firm began operations in January 2016. Also, your firm does not receive a Certificate of Analysis for **(b)(4)** used for sterile operations.

b.) Equipment used in sterile operations are not on a calibration program to be calibrated at any frequency. The following pieces of equipment have not been calibrated since your firm began operations in January 2016: **(b)(4)** incubators, and **(b)(4)**. Your **(b)(4)** scale (model #: **(b)(4)**; serial number: **(b)(4)**) used for weighing materials for sterile operations is past due for calibration. On 8/21/18, we observed this scale had a due date sticker of 7/31/18.

c.) The digital temperature recorder of your refrigerator **(b)(4)**; model #: **(b)(4)**: serial #: **(b)(4)** used for storing finished drug product has never been calibrated. Your firm has been using this refrigerator in your pharmacy since January 2016.

d.) Your firm has not qualified your **(b)(4)**, **(b)(4)**, and **(b)(4)** used for producing sterile drugs at your facility.

*DATES OF INSPECTION*
8/20/2018(Mon), 8/21/2018(Tue), 8/22/2018(Wed), 8/23/2018(Thu), 8/24/2018(Fri), 8/29/2018(Wed), 8/30/2018(Thu), 8/31/2018(Fri), 9/05/2018(Wed), 9/06/2018(Thu), 9/07/2018(Fri), 9/11/2018(Tue), 9/13/2018(Thu), 10/02/2018(Tue), 10/03/2018(Wed), 10/24/2018(Wed)